Wilkin T J, Crooks J, Jaffiol C, Baldet L
Ann Endocrinol (Paris). 1981 Apr-Jun;42(2):121-30.
The early (20-min.) radioiodine uptake was used to monitor disease activity in 35 Graves' patients undergoing an 18-month course of treatment with carbimazole and T3. T3 alone produced no change in uptake, but four weeks after the introduction of carbimazole, the mean uptake had fallen by more than 50%. Six months after completion of treatment, 20 patients (group R) had relapsed, and 15 (group E) were in remission. The only quantitative difference in mean uptake behaviour between R and E patients was one of degree, their slopes being parallel. Thus, while the mean uptake of both groups fell progressively towards normal, that of group E patients arrived much the earlier, and carbimazole seemed to hasten both. Major fluctuations in thyroid uptake were observed in most individuals, but certain defined patterns emerged. While the uptake suppressed at some time during treatment in 32 (91,4%) patients, remission was associated only with early (ie before month 5) and stable suppression. The predictive value of the uptake test early during treatment was limited to identifying a group certain to relapse, but these non-suppressors accounted for only 40% of all patients, and it was not possible to identify with any certainty those who would ultimately remit.
对35例接受为期18个月的卡比马唑和T3治疗的格雷夫斯病患者,采用早期(20分钟)放射性碘摄取来监测疾病活动情况。单独使用T3时摄取量无变化,但引入卡比马唑四周后,平均摄取量下降超过50%。治疗结束六个月后,20例患者(R组)复发,15例(E组)缓解。R组和E组患者平均摄取行为的唯一定量差异在于程度,其斜率平行。因此,虽然两组的平均摄取量都逐渐趋向正常,但E组患者的摄取量更早达到正常,且卡比马唑似乎加速了这一过程。大多数个体观察到甲状腺摄取有较大波动,但出现了某些特定模式。虽然32例(91.4%)患者在治疗期间的某个时间摄取受到抑制,但缓解仅与早期(即第5个月之前)和持续抑制有关。治疗早期摄取试验的预测价值仅限于识别出肯定会复发的一组患者,但这些非抑制者仅占所有患者的40%,无法确切识别出最终会缓解的患者。